A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer (DFCI/HCC 17-512)

Study Details

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

Learn more

ClinicalTrials.gov NCT number

Principal Investigators

  • Steve Lo, MD
Dana-Farber Cancer Institute
Mary Miller, LPN at 203-358-8879
or officeofresearch@stamhealth.org


  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695